Sildenafil in hypoxic pulmonary hypertension potentiates a compensatory up-regulation of NO-cGMP signaling

FASEB Journal

Volumn 22, Issue 1, 2008, Pages 30-40

  Kirsch, Mark ^a   Kemp Harper, Barbara ^b   Weissmann, Norbert ^c   Grimminger, Friedrich ^c   Schmidt, Harald H H W ^b  

^a JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

^b MONASH UNIVERSITY   (Australia)

^c JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

Author keywords

Lung perfusate; PH; Vascular disease

Indexed keywords

3 NITROTYROSINE; CYCLIC GMP; GUANYLATE CYCLASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PHOSPHODIESTERASE V; SILDENAFIL; VASODILATOR STIMULATED PHOSPHOPROTEIN; PHOSPHODIESTERASE INHIBITOR; PIPERAZINE DERIVATIVE; PURINE DERIVATIVE; SULFONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HYPOXIA; LUNG ARTERY PRESSURE; LUNG VASOCONSTRICTION; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PULMONARY HYPERTENSION; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; ANOXIA; C57BL MOUSE; LUNG; METABOLISM; PATHOPHYSIOLOGY; PHOSPHORYLATION;

MUS;

ANIMALS; ANOXIA; CYCLIC GMP; HYPERTENSION, PULMONARY; LUNG; MALE; MICE; MICE, INBRED C57BL; NITRIC OXIDE; PHOSPHODIESTERASE INHIBITORS; PHOSPHORYLATION; PIPERAZINES; PURINES; SIGNAL TRANSDUCTION; SULFONES; UP-REGULATION;

EID: 38049132717     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.06-7526com     Document Type: Article

References (72)

1. Ignarro, L. J., Byrns, R. E., Buga, G. M., and Wood, K. S. (1987) Endothelium-derived relaxing factor from pulmonary artery and vein possesses pharmacologic and chemical properties identical to those of nitric oxide radical. Circ. Res. 61, 866-879
2. Ignarro, L. J., Byrns, R. E., Buga, G. M., Wood, K. S., and Chaudhuri, G. (1988) Pharmacological evidence that endothelium-derived relaxing factor is nitric oxide: use of pyrogallol and superoxide dismutase to study endothelium-dependent and nitric oxide-elicited vascular smooth muscle relaxation. J. Pharmacol. Exp. Ther. 244, 181-189
3. Feil, R., Gappa, N., Rutz, M., Schlossmann, J., Rose, C. R., Konnerth, A., Brummer, S., Kuhbandner, S., and Hofmann, F. (2002) Functional reconstitution of vascular smooth muscle cells with cGMP-dependent protein kinase I isoforms. Circ. Res. 90, 1080-1086
4. Adnot, S., Raffestin, B., Eddahibi, S., Braquet, P., and Chabrier, P. E. (1990) Loss of endothelium-dependent relaxant activity in the pulmonary circulation of rats exposed to chronic hypoxia. J. Clin. Invest. 87, 155-162
5. Rodman, D. M., Yamaguchi, T., Hasunuma, K., O'Brien, R. F., and McMurtry, I. F. (1990) Effects of hypoxia on endothelium-dependent relaxation of rat pulmonary artery. Am. J. Physiol. 258, L207-L214
6. Ghofrani, H. A., Wiedemann, R., Rose, F., Schermuly, R. T., Olschewski, H., Weissmann, N., Gunther, A., Walmrath, D., Seeger, W., and Grimminger, F. (2002) Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trail. Lancet 360, 895-900
7. Bharani, A., Mathew, V., Sahu, A., and Lunia, B. (2003) The efficacy and tolerability of sildenafil in patients with moderate-to-severe pulmonary hypertension. Indian Heart J. 55, 285
8. Sebkhi, A., Strange, J. W., Phillips, S. C., Wharton, J., and Wilkins, M. R. (2003) Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension. Circulation 107, 3230-3235
9. Zhao, L., Mason, N. A., Morrell, N. W., Kojonazarov, B., Sadykov, A., Maripov, A., Mirrakhimov, M. M., Aldashev, A., and Wilkins, M. R. (2001) Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation 104, 424-428
10. Zhao, L., Mason, N. A., Strange, J. W., Walker, H., and Wilkins, M. R. (2003) Beneficial effects of phosphodiesterase 5 inhibition in pulmonary hypertension are influenced by natriuretic peptide activity. Circulation 107, 234-237
11. Dumitrascu, R., Weissmann, N., Ghofrani, H. A., Dony, E., Beuerlein, K., Schmidt, H. H. H. W., Stasch, J. P., Gnoth, M. J., Seeger, W., Grimminger, F., and Schermuly, R. T. (2006) Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling. Circulation 113, 286-295
12. Evgenov, O. V., Ichinose, F., Evgenov, N. V., Gnoth, M. J., Falkowski, G. E., Chang, Y., Bloch, K. D., and Zapol, W. M. (2004) Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs. Circulation 110, 2253-2259
13. Frank, D. U., Horstman, D. J., Morris, G. N., Johns, R. A., and Rich, G. F. (1998) Regulation of the endogenous NO pathway by prolonged inhaled NO in rats. J. Appl. Physiol. 85, 1070-1078
14. Murata, T., Sato, K., Hori, M., Ozaki, H., and Karaki, H. (2002) Decreased endothelial nitric-oxide synthase (eNOS) activity resulting from abnormal interaction between eNOS and its regulatory proteins in hypoxia-induced pulmonary hypertension. J. Biol. Chem. 277, 44085-44092
15. Shaul, P. W., North, A. J., Brannon, T. S., Ujiie, K., Wells, L. B., Nisen, P. A., Lowenstein, C. J., Snyder, S. H., and Star, R. A. (1995) Prolonged in vivo hypoxia enhances nitric oxide synthase type I and type III gene expression in adult rat lung. Am. J. Respir. Cell Mol. Biol. 13, 167-174
16. Xue, C., Rengasamy, A., Le Cras, T. D., Koberna, P. A., Dailey, G. C., and Johns, R. A. (1994) Distribution of NOS in normoxic vs. hypoxic rat lung: upregulation of NOS by chronic hypoxia. Am. J. Physiol. 267, L667-L678
17. Xue, C., and Johns, R. A. (1996) Upregulation of nitric oxide synthase correlates temporally with onset of pulmonary vascular remodeling in the hypoxic rat. Hypertension 28, 743-753
18. Le Cras, T. D., Xue, C., Rengasamy, A., and Johns, R. A. (1996) Chronic hypoxia upregulates endothelial and inducible NO synthase gene and protein expression in rat lung. Am. J. Physiol. 270, L164-L170
19. Fagan, K. A., Tyler, R. C., Sato, K., Fouty, B. W., Morris, K. G., Huang, P. L., McMurtry, I. F., and Rodman, D. M. (1999) Relative contributions of endothelial, inducible, and neuronal NOS to tone in the murine pulmonary circulation. Am. J. Physiol. 277, L472-L478
20. Demiryürek, A. T., Karamsetty, M. R., McPhaden, A. R., Wadsworth, R. M., Kane, K. A., and MacLean, M. R. (2000) Accumulation of nitrotyrosine correltates with endothelial NO synthase in pulmonary resistance arteries during chronic hypoxia in the rat. Pulmon. Pharmacol. Ther. 13, 157-165
21. Li, D., Laubach, V. E., and Johns, R. A. (2001) Upregulation of lung soluble guanylate cyclase during chronic hypoxia is prevented by deletion of eNOS. Am. J. Physiol. 281, L369-L376
22. Muzaffar, S., Shukla, N., Angelini, G. D., and Jeremy, J. Y. (2005) Acute hypoxia simultaneously induces the expression of gp91phox and endothelial nitric oxide synthase in the porcine pulmonary artery. Thorax 60, 305-313
23. Xia, X. D., Xu, Z. J., Bi, Y. T., Dai, Y. R., and Wu, S. Z. (2003) Study on soluble guanylate cyclase in pulmonary hypertension rat model Zonghua. Nei Ke Za Zhi 42, 628-631
24. Jernigan, N. L., and Resta, T. C. (2002) Chronic hypoxia attenuates cGMP-dependent pulmonary vasodilation. Am. J. Physiol. 282, L1366-L1375
25. Li, D., Zhou, N., and Johns, R. A. (1999) Soluble guanylate cyclase gene expression and localization in rat lung after exposure to hypoxia. Am. J. Physiol. 277, L841-L847
26. Reiter, C. D., Teng, R. J., and Beckman, J. S. (2000) Superoxide reacts with nitric oxide to nitrate tyrosine at physiological pH via peroxynitrite. J. Biol. Chem. 275, 32460-23466
27. Polson, J. B., and Strada, S. J. (1996) Cyclic nucleotide phosphodiesterases and vascular smooth muscle. Annu. Rev. Pharmacol. Toxicol. 36, 403-427
28. Kotera, J., Fujishige, K., and Omori, K. (2000) Immunohistochemical localization of cGMP-binding cGMP-specific phosphodiesterase (PDE 5) in rat tissues. J. Histochem. Cytochem. 48, 685-693
29. Murray, F., MacLean, M. R., and Pyne, N. J. (2002) Increased expression of the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension. Br. J. Pharmacol. 137, 1187-1194
30. Maclean, M. R., Johnston, E. D., McCulloch, K. M., Pooley, L., Houslay, M. D., and Sweeney, G. (1997) Phosphodiesterase isoforms in the pulmonary arterial circulation of the rat: changes in pulmonary hypertension. J. Pharmacol. Exp. Ther. 283, 619-624
31. Grimminger, F., Spriestersbach, R., Weissmann, N., Walmrath, D., and Seeger, W. (1995) Nitric oxide generation and hypoxic vasocontriction in buffer-perfused rabbit lungs. J. Appl. Physiol. 78, 1509-1515
32. Turley, J., Nelin, L., Kaplowitz, M. R., Zhang, Y., and Fike, C. D. (2003) Exhaled NO is reduced at an early stage of hypoxia-induced pulmonary hypertension in newborn piglets. Am. J. Physiol. 284, L489-L500
33. Weissmann, N., Nollen, M., Gerigk, B., Ghofrani, H. A., Schermuly, R. T., Gunther, A., Quanz, K., Fink, L., Hanze, J., Rose, F., et al. (2003) Downregulation of hypoxic vasoconstriction by chronic hypoxia in rabbits: effects of nitric oxide. Am. J. Physiol. 284, H931-H938
34. Isaacson, T. C., Hampl, V., Weir, E. K., Nelson, D. P., and Archer, S. L. (1994) Increased endothelium-derived NO in hypertensive pulmonary circulation of chronically hypoxic rats. J. Appl. Physiol. 76, 933-940
35. Muramatsu, M., Tyler, R. C., Rodman, D. M., and McMurtry, I. F. (1996) Thapsigargin stimulates increased NO activity in hypoxic hypertensive rat lungs and pulmonary arteries. J. Appl. Physiol. 80, 1336-1344
36. Cohen, A. H., Hanson, K., Morris, K., Fouty, B., McMurty, I. F., Clarke, W., and Rodman, D. M. (1996) Inhibition of cyclic 3′-5′-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats. J. Clin. Invest. 97, 172-179
37. Crawley, D. E., Zhao, L., Giembycz, M. A., Liu, S., Barnes, P. J., Winter, R. J., and Evans, T. W. (1992) Chronic hypoxia impairs soluble guanylyl cyclase-mediated pulmonary arterial relaxation in the rat. Am. J. Physiol. 263, L325-L332
38. Johns, R. A., Linden, J. M., and Peach, M. J. (1989) Endothelium- dependent relaxation and cyclic GMP accumulation in rabbit pulmonary artery are selectively impaired by moderate hypoxia. Circ. Res. 65, 1508-1515
39. Hanasato, N., Oka, M., Muramatsu, M., Nishino, M., Adachi, H., and Fukuchi, Y. (1999) E-4010, a selective phosphodiesterase 5 inhibitor, attenuates hypoxic pulmonary hypertension in rats. Am. J. Physiol. 277, L225-L232
40. Feil, R., and Kemp-Harper, B. (2006) cGMP signaling: from bench to bedside. Conference on cGMP generators, effectors and therapeutic implications. EMBO Rep. 7, 149-153
41. Jernigan, N. L., Walker, B. R., and Resta, T. C. (2003) Pulmonary PKG-1 is upregulated following chronic hypoxia. Am. J. Physiol. 285, L634-L642
42. Oelze, M., Mollnau, H., Hoffmann, N., Warnholtz, A., Bodenschatz, M., Smolenski, A., Walter, U., Skatchkov, M., Meinertz, T., and Münzel, T. (2000) Vasodilator-stimulated phosphoprotein serine 239 phosphorylation as a sensitive monitor of defective nitric oxide/cGMP signaling and endothelial dysfunction. Circ. Res. 87, 999-1005
43. Ibarra-Alvarado, C., Galle, J., Melichar, V. O., Mameghani, A., and Schmidt, H. H. H. W. (2002) Phosphorylation of blood vessel vasodilator- stimulated phosphoprotein at serine 239 as a functional biochemical marker of endothelial nitric oxide/cyclic GMP signaling. Mol. Pharmacol. 61, 312-319
44. Warnholtz, A., Ostad, M.A., Velich, N., Trautmann, C., Schinzel, R., Walter, U., and Münzel, T. (2007) A single loading dose of clopidogrel causes dose-dependent improvement of endothelial dysfunction in patients with stable coronary artery disease: Results of a double-blind, randomized study. Arthersclerosis In press
45. Weissmann, N., Manz, D., Buchspies, D., Keller, S., Mehling, T., Voswinckel, R., Quanz, K., Ghofrani, H. A., Schermuly, R. T., Fink, L., et al. (2005) Congenital erythropoetin over-expression causes "anti-pulmonary hypertensive" structural and functional changes in mice, both in normoxia and hypoxia. Thromb. Haemost. 94, 630-638
46. Weissmann, N., Akkayagil, E., Quanz, K., Schermuly, R. T., Ghofrani, H. A., Fink, L., Hanze, J., Rose, F., Seeger, W., and Grimminger, F. (2004) Basic features of hypoxic pulmonary vasocontriction in mice. Respir. Physiol. Neurobiol. 139, 191-202
47. Lowry, O. H., Rosebrough, N. J., Farr, A. L., and Randall, R. J. (1951) Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193, 265-275
48. Galle, J., Zabel, U., Hübner, U., Hatzelmann, A., Wagner, B., Wanner, C., and Schmidt, H. H. H. W. (1999) Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels, and. phosphodiesterase. activity. Br. J. Pharmacol. 127, 195-203
49. Zabel, U., Weeger, M., La, M., and Schmidt, H. H. H. W. (1998) Human soluble guanylate cyclase: functional expression and revised isoenzyme family. Biochem. J. 127, 195-203
50. Markert, T., Vaandrager, A. B., Gambaryan, S., Pöhler, D., Häusler, C., Walter, U., De Jonge, H. R., Jarchau, T., and Lohmann, S. L. (1995) Endogenous expression of type II cGMP-dependent protein kinase mRNA and protein in rat intestine. Implications for cystic fibrosis transmembrane conductance regulator. J. Clin. Invest. 96, 822-830
51. Smolenski, A., Bachmann, C., Reinhard, K., Honig-Liedl, P., Jarchau, T., Hoschuetzky, H., and Walter, U. (1998) Analysis and regulation of vasodilator-stimulated phosphoprotein serine 239 phosphorylation in vitro and in intact cells using a phosphospecific monoclonal antibody. J. Biol. Chem. 273, 20029-20035
52. Kahl, K. G., Zielasek, J., Uttenthal, L. O., Rodrigo, J., Toyka, K. V., and Schmidt, H. H. H. W. (2003) Protective role of the cytokine-inducible isoform of nitric oxide synthase induction and nitrosative stress in experimental autoimmune encephalomyelitis of the DA rat. Neurosci. Res. 73, 198-205
53. Beckmann, J. S., Ye, Y. Z., Anderson, P. G., Chen, J., Accavitti, M. A., Tarpey, M. M., and White, C. R. (1994) Extensive nitration of protein tyrosines in human atherosclerosis detected by immunohistochemistry. Biol. Chem. Hoppe Seyler 375, 81-88
54. Koesling, D., Harteneck, C., Humbert, P., Bosserhoff, A., Frank, R., Schultz, G., and Bohme, E. (1990) The primary structure of the larger subunit of soluble guanylyl cyclase from bovine lung. Homology between the two subunits of the enzyme. FEBS Lett. 266, 128-132
55. Schermuly, R. T., Pullamsetti, S. S., Kwapiszewska, G., Dumitrascu, R., Tian, X., Weissmann, N., Ghofrani, H. A., Kaulen, C., Dunkern, T., Schudt, C., et al. (2007) Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: target for reverse-remodeling therapy. Circulation 115, 2331-2339
56. Pauvert, O., Bonnet, S., Rousseau, E., Marthan, R., and Savineau, Jean-Pierre (2004) Sildenafil alters calcium signaling and vascular tone in pulmonary arteries form chronically hypoxic rats. Am. J. Physiol. 287, L577-L583
57. Preston, I. R., Hill, N. S., Gambardella, L. S., Warburton, R. R., and Klinger, R. (2004) Synergistic effects of ANP and sildenafil on cGMP levels and amelioration of acute hypoxic pulmonary hypertension. Exp. Biol. Med. 229, 920-925
58. Goyal, P., Weissmann, N., Grimminger, F., Hegel, C., Bader, L., Rose, F., Fink, L., Ghofrani, H. A., Schermuly, R. T., Schmidt, H. H. H. W., et al. (2004) Upregulation of NAD(P)H oxidase 1 in hypoxia activates hypoxia-inducible factor 1 via increase in reactive oxygen species. Free Radic. Biol. Med. 36, 1279-1288
59. Wingler, K., Wunsch, S., Kreutz, R., Rothermund, L., Paul, M., and Schmidt, H. H. H. W. (2001) Upregulation of the vascular NAD(P)H-oxidase isoforms Nox1 and Nox4 by the renin-angiotensin system in vitro and in vivo. Free Radic. Biol. Med. 31, 1456-1464
60. Valencia, A., Rajadurai, A., Carle, A. B., and Kochevar, I. E. (2006) 7-Dehydrocholesterol enhances ultraviolet A-induced oxidative stress in keratinocytes: roles of NADPH oxidase, mitrochondria, and lipid rafts. Free Radic. Biol. Med. 41, 1704-1718
61. Martyn, K. D., Frederick, L. M., von Loehneysen, K., Dinauer, M. C., and Knaus, U. G. (2006) Functional analysis of Nox 4 reveals unique characteristics compared to other NADPHoxidases. Cell Signal. 18, 69-82
62. Phillips, P. G., Long, L., Wilkins, M. R., and Morrell, N. W. (2005) cAMP phosphodiesterase inhibitors potentiate effects of prostacyclin analogs in hypoxic pulmonary vascular remodeling. Am. J. Physiol. 288, L103-L115
63. Murray, F., Patel, H. H., Suda, R. Y., Zhang, S., Thistlewaite, P., Yuan, J. X., and Insel, P. A. (2007) Expressions and activity of cAMP phosphodiesterase isoforms in pulmonary artery smooth muscle cells from patients with pulmonary hypertension: Role for PDE1. Am. J. Physiol. 292, L294-L303
64. Lugnier, C., Keravis, T., and Eckly-Michel, A. (1999) Cross talk between NO and cyclic nucleotide phosphodiesterases in the modulation of signal transduction in blood vessles. J. Physiol. Pharmacol. 50, 639-652
65. Weissmann, N., Dietrich, A., Fuchs, B., Kalwa, H., Ay, M., Dumitrascu, R., Olschewski, A., Storch, U., Mederos v. Schnitzler, M., Ghofrani, H. A., et al. (2006) Classical transient receptor channel 6 (TRPC6) is essential for hypoxic pulmonary vasoconstriction and alveolar gas exchange. Proc. Natl. Acad. Sci. U. S. A. 103, 19093-19098
66. Schermuly, R. T., Dony, E., Ghofrani, A., Pullamsetti, S., Savai, R., Roth, M., Sydykov, A., Lai, Y. J., Weissmann, N., Seeger, W., and Grimminger, F. (2005) Reversal of experimental pulmonary hypertension by PDGF inhibition. J. Clin. Invest. 115, 2811-2821
67. Krick, S., Hänze, J., Eul, B., Savai, R., Seay, U., Grimminger, F., Lohmeyer, J., Klepetko, W., Seeger, W., and Rose, F. (2005) Hypoxia-driven proliferation of human pulmonary artery fibroblasts: cross-talk between HIF-1 (alpha) and an autocrine angiotensin system. FASEB J. 19, 857-859
68. Fukumoto, Y., Tawara, S., and Shimokawa, H. (2007) Recent progress in the treatment of pulmonary arterial hypertension: Expectation for Rho-Kinase Inhibitors. Tohoku J. Exp. Med. 211, 309-320
69. Sauzeau, V., Rolli-Derkinderen, M., Lehoux, S., Loirand, G., and Pacaud, P. (2003) Sildenafil prevents change in RhoA expression induced by chronic hypoxia in rat pulmonary artery. Circ. Res. 93, 630-637
70. Rubin, L. J., Badesch, M. D., Barst, R. J., Galie, N., Black, C. M., Keogh, A., Pulido, T., Frost, A., Roux, S., Leconte, I., et al. (2002) Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med. 346, 896-903
71. Herve, P., Launay, J. M., and Scrobohaci, M. L. (1995) Increased plasma serotonin in primary pulmonary hypertension. Am. J. Med. 99, 249-254
72. Petkov, V., Mosgoeller, W., and Ziesche, R. (2003) Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J. Clin. Invest. 111, 1339-1346